All Stories

  1. Are we donating iron? Impact of apheresis on ferritin
  2. Indices of iron homeostasis in asymptomatic subjects with HFE mutations and moderate ferritin elevation during iron removal treatment
  3. Pathogen inactivation treatment of triple‐dose apheresis platelets with amotosalen and ultraviolet a light
  4. Frequency, reactivity and evolution of human leukocyte antigen and human platelet antigen antibodies in the setting of hematopoietic cell transplantation
  5. Immune cytopenia after allogeneic haematopoietic stem-cell transplantation: challenges, approaches, and future directions
  6. Identification of Patients with Cobalamin Deficiency Crucially Depends on the Diagnostic Strategy
  7. Extracorporeal Photopheresis in Graft-versus-Host Disease
  8. Impact of Amotosalen/UVA Pathogen Inactivated Platelet Components on Outcomes after Allogeneic Hematopoetic Stem Cell Transplantation: A Single Center Analysis
  9. Clinical impact of amotosalen‐ultraviolet A pathogen‐inactivated platelets stored for up to 7 days
  10. Transfusion de plaquettes traitées par amotosalen conservées jusqu’à 7 jours
  11. The Remarkable Journey of a Low-Frequency Alloantibody
  12. The value of the post-thaw CD34+ count with and without DMSO removal in the setting of autologous stem cell transplantation
  13. Current hepatitis E virus seroprevalence in Swiss blood donors and apparent decline from 1997 to 2016
  14. Baseline calprotectin fails to predict incidence of acute gastrointestinal graft vs. host disease: a prospective study
  15. International Forum on typing and matching strategies in patients on anti-CD38 monoclonal therapy
  16. Vox Sanguinis International Forum on typing and matching strategies in patients on anti-CD38 monoclonal therapy: summary
  17. Handling, processing and disposal of stem cell products in Europe: A survey by the cellular therapy and immunobiology working party of the European Society for Blood and Marrow Transplantation
  18. In response to the comment by Hechler et al .: Amotosalen/UVA pathogen inactivation technology reduces platelet activatability, induces apoptosis and accelerates clearance.
  19. Role of liver magnetic resonance imaging in hyperferritinaemia and the diagnosis of iron overload
  20. Red cell apheresis: pros and cons
  21. Amotosalen/ultraviolet A pathogen inactivation technology reduces platelet activatability, induces apoptosis and accelerates clearance
  22. Human platelet antigen antibody induction in uncomplicated pregnancy is associated with HLA sensitization
  23. Haploidentical hematopoietic bone marrow transplantation followed by living kidney transplantation from the same donor in a sickle cell disease patient with end-stage renal failure
  24. Iron deficiency and thrombocytosis
  25. International Forum regarding practices related to donor haemoglobin and iron
  26. Impact of donor ABH‐secretor status in ABO‐mismatched living donor kidney transplantation
  27. MNSs genotyping by MALDI-TOF MS shows high concordance with serology, allows gene copy number testing and reveals new St(a) alleles
  28. Temperature-Sensitive Indicators for Monitoring RBC Concentrates Out of Controlled Temperature Storage
  29. Blood donor to inactive donor transition in the Basel region between 1996 and 2011: a retrospective cohort study
  30. Management of a Pregnant Woman with Anti-Holley Alloantibody
  31. The Intercept Blood System Affects Platelet Function and Survival By Inducing Apoptosis
  32. Impact of recipient ABH secretor status on outcome in minor ABO-incompatible hematopoietic stem cell transplantation
  33. Platelet transfusion: basic aspects
  34. Pattern of care of blood donors with early-uncomplicated hereditary haemochromatosis in a Swiss blood donation centre
  35. Role of donor and recipient sex in platelet transfusion
  36. Comparison of transfusion efficacy of amotosalen‐based pathogen‐reduced platelet components and gamma‐irradiated platelet components
  37. Quantity of HLA-C surface expression and licensing of KIR2DL+ natural killer cells
  38. Switching iron-deficient whole blood donors to plateletpheresis
  39. Prospective change control analysis of transfer of platelet concentrate production from a specialized stem cell transplantation unit to a blood transfusion center
  40. Prognostic value of red blood cell parameters and ferritin in predicting deferral due to low hemoglobin in whole blood donors
  41. Pathogen-inactivation of platelet components with the INTERCEPT Blood System™: A cohort study
  42. The value of routine ferritin measurement in blood donors
  43. A pilot Iron Substitution Programme in female blood donors with iron deficiency without anaemia
  44. The Value of Routine Ferritin Measurement In Blood Donors
  45. Prevalence of Polyomavirus BK and JC Infection and Replication in 400 Healthy Blood Donors
  46. ABO blood group-incompatible living donor kidney transplantation: a prospective, single-centre analysis including serial protocol biopsies